Trial Number
376-23
Condition
Migraine & Headache
Participant Age Range
6 years to 17 years
Participant Gender
Any
Enrolling Participants
Yes
Overview
“Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1”
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.